52North Selected from over 2,000 for NATO DIANA Programme

52North is a Cambridge-based medtech and digital health company that is revolutionising urgent care pathways by developing low-cost, digitally integrated diagnostic tests. Cancer Research Horizons invested in 52North via its Seed Fund in 2024.

DIANA (Defence Innovation Accelerator for the North Atlantic) is a NATO organisation with a mission to locate and accelerate innovation across the Alliance. DIANA provides resources, networks, and expertise to address critical defence and security challenges.

Along with 19 companies, 52North was selected among 2,600 applicants to join this competitive accelerator programme from January 2025. The programme is directed to deep-tech innovators who are working on solutions in five challenge areas with potential to change the landscape of defence, security, and resilience.

52North is honoured to be chosen as a 'Human Health and Performance' Innovator, where the programme will provide the opportunity to further develop and showcase 52North technologies for greater health impact.